{
    "clinical_study": {
        "@rank": "144475", 
        "acronym": "GT-17", 
        "arm_group": [
            {
                "arm_group_label": "Electronic compliance device", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX\u00ae) using an electronic compliance device (Memozax\u00ae)"
            }, 
            {
                "arm_group_label": "No electronic compliance device", 
                "arm_group_type": "No Intervention", 
                "description": "Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX\u00ae) without any electronic compliance device (Memozax\u00ae)"
            }
        ], 
        "brief_summary": {
            "textblock": "Adherence to treatment is crucial to the efficacy of sublingual immunotherapy of allergic\n      diseases. GRAZAX\u00ae is a  registered drug in Europe, with established efficacy in the\n      treatment of allergic rhinitis, which has to be taken daily by patients. This study was\n      aimed to establish if a device with the characteristics of a mechanical dispenser (Memozax\u00ae)\n      could improve adherence to treatment in subjects with hay fever due to allergy to grass"
        }, 
        "brief_title": "Compliance to the Treatment With GRAZAX\u00ae Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis", 
        "completion_date": {
            "#text": "October 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Allergic Rhinitis", 
            "Grass Allergy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis", 
                "Conjunctivitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A clinical history of grass pollen-induced allergic rhinoconjunctivitis (with or\n             without asthma) having received treatment during the previous grass pollen season.\n\n          -  Positive skin prick test (SPT) response (wheal diameter \u22653mm) to Phleum pratense\n\n          -  Positive specific IgE against Phleum pratense (IgE titer > class 2)\n\n        Exclusion Criteria:\n\n          -  Clinical history of chronic sinusitis during the last 2 years or of symptomatic\n             perennial or seasonal allergic rhinitis and/or asthma having received regular\n             medication, due to another allergen during - or potentially overlapping - the grass\n             pollen season.\n\n          -  Clinical history of severe asthma (GINA Step 4 and children with Forced Expiratory\n             Volume in 1 second (FEV1) < 80% of expected value after treatment with inhaled\n             corticosteroids and short-acting \u03b22 agonists)\n\n          -  Previous treatment by immunotherapy with grass pollen allergen or any other allergen\n             within the previous 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "261", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728285", 
            "org_study_id": "GT-17 ITALY", 
            "secondary_id": "2006-004820-35"
        }, 
        "intervention": {
            "arm_group_label": "Electronic compliance device", 
            "description": "An electronic compliance device is distributed to patients allocated to the active arm", 
            "intervention_name": "Electronic compliance device (Memozax\u00ae)", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "specific allergen immunotherapy", 
            "sublingual immunotherapy", 
            "allergen tablets", 
            "compliance", 
            "electronic compliance device"
        ], 
        "lastchanged_date": "November 14, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pavia", 
                    "country": "Italy", 
                    "state": "PV", 
                    "zip": "27100"
                }, 
                "name": "Fondazione IRCCS Policlinico San Matteo"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicentric Open Randomised, Cross-over Phase III Trial Assessing the Treatment Compliance With GRAZAX\u00ae in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate if compliance of once daily dosing with Grazax in adult subjects with grass pollen induced allergic rhinoconjunctivitis can be increased by providing patients with an electronic compliance device. Compliance in the two groups (with Memozax and without Memozax) was evaluated by tablet counts", 
            "measure": "To evaluate if compliance with grass Allergy Immunotherapy Tablet can be increased by providing an electronic compliance device (CED) (Memozax; a tablet-container with a programmable daily acoustic alarm)", 
            "safety_issue": "No", 
            "time_frame": "up to 1 year per patient"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728285"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "22131999", 
            "citation": "Alesina R, Milani M, Pecora S. A multicenter, randomized, parallel-group trial assessing compliance, tolerability, safety, and efficacy to treatment with grass allergy tablets in 261 patients with grass pollen rhinoconjunctivitis. J Allergy (Cairo). 2012;2012:673502. doi: 10.1155/2012/673502. Epub 2011 Nov 9."
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate after one-year treatment with Grazax tablets the impact on quality of life in comparison with previous pollen seasons", 
                "measure": "Impact of GRAZAX\u00ae treatment on QoL as compared to previous season", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year per patient"
            }, 
            {
                "description": "To evaluate after one-year treatment with Grazax tablets the impact on symptom score in comparison with previous pollen seasons", 
                "measure": "Impact of GRAZAX\u00ae treatment on allergy symptoms as compared to previous season", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year per patient"
            }, 
            {
                "description": "To evaluate after one-year treatment with Grazax tablets the impact on patient's acceptance in comparison with previous pollen seasons", 
                "measure": "Impact of GRAZAX\u00ae on treatment acceptance as compared to previous season", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year per patient"
            }, 
            {
                "description": "The safety assessments included recording of all adverse events (AE) and serious adverse events (SAE) findings from physical examinations and from vital signs", 
                "measure": "Recording of all adverse events and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year per patient"
            }
        ], 
        "source": "ALK-Abell\u00f3 A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ALK-Abell\u00f3 A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2007", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}